Look back at pharma news in the week to September 27

29 September 2019

By Barbara Obstoj-Cardwell. Editor

Regulatory news last week included US Food and Drug Administration approval for Danish diabetes care giant Novo Nordisk’s Rybelsus the oral formulation of semaglutide. GlaxoSmithKline announced an additional investment of $120 million in its US manufacturing facilities. On the political front, the UK opposition Labour party announced its intention to set up a state-owned company to produce generics and also said it would use compulsory licensing if it wins the next election. In terms of research results, G1 Therapeutics’ mid-stage breast cancer drug trilaciclib has been attracting attention.

Pricing questions remain as Novo Nordisk gets the nod for oral semaglutide

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK